Categories

Share:

New Corporate Brochure

February 17, 2020

To make your choice easier and faster 4bases’ company and product information are gathered in the new brochure

Share:

Categories

More Posts

4bases’Paper of the Month – May 2024 – Correlation between NGS panel-based mutation results and clinical information in colorectal cancer patients

Colorectal cancer stands out globally as a prevalent cancer type driven by genetic and epigenetic alterations, making personalised treatment challenging due to the uncertainty surrounding

4bases’Paper of the Month – April 2024 – A clinical ready, long reads solution for sequencing human microbiota

The human microbiome inhabits diverse microbial communities containing various body sites, establishing a symbiotic equilibrium within the host. Throughout our lifespan, these communities undergo changes

4bases’paper of The Month – March 2024 -Hereditary cancer syndrome-associated pathogenic variants are common in patients with hematologic malignancies subsequent to primary solid cancer

The need for genetic diagnosis of hemato-oncology diseases is steadily increasing, driven by the advent of precision medicine. This month’s recommended reading: “Hereditary cancer syndrome-associated

4bases’paper of The Month – February 2024 – Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy

TP53, the gene encoding the p53 protein, stands out as the most frequently mutated gene in cancers, affecting approximately 50% of patients. While the normal

Powered by Lifency SA © 2025